pISSN 1226-6051
eISSN 2508-786X

Table. 5.

Table. 5.

Treatment of rapid cycling across practice guideline

Guidelines First-line treatment Next-step intervention Later intervention
KMAP-BP 2022 · Currently manic: MS + AAP, Val, Li, QUE, ARI, OLA, RIS
· Currently depressed: MS + AAP, QUE, ARI, Li, Val, OLA, AAP + LMT, MS + LMT
· Currently manic: 2MSs. MS + LMT, AAP + LMT, MS + TAP, ECT
· Currently depressed: LMT, 2MSs, MS + AAP + AD, MS + AD, MS + TAP, ECT
· Currently manic: MS + AD
· Currently depressed: AD
BAP 2016 No recommendation
CANMAT 2018 No recommendation
CINP-BD-2017 ARI, QUE, Val OLA, Li MS + QUE (or RIS)
NICE 2014 Same as with other types of bipolar disorder
RANZCP 2020 No recommendation

AAP, atypical antipsychotics; AD, antidepressant; ARI, aripiprazole; BAP 2016, The British Association for Psychopharmacology Guidelines for Treatment for Bipolar Disorder 2016; CANMAT 2018, Canadian Network for Mood and Anxiety Treatments 2018; CINP-BD 2017, The International College of Neuropsychopharmacology Treatment Guidelines for Bipolar Disorder 2017; ECT, electroconvulsive therapy; KMAPBP 2022, Korean Medication Algorithms for Bipolar Disorder 2022; Li, lithium; LMT, lamotrigine; MS, mood stabilizer; NICE 2014, National Institute for Health and Clinical Excellence Treatment for Bipolar Disorder; OLA, olanzapine; QUE, quetiapine; RANZCP 2020, The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders; RIS, risperidone; TAP, typical antipsychotics; Val, various kinds of valproic acids.

Korean J Clin Pharm 2023;33:153-67 https://doi.org/10.24304/kjcp.2023.33.3.153
© 2023 Korean J Clin Pharm